Acuvi (ACUVI) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
21 Aug, 2025Executive summary
Revenue for Q2 2025 increased by 9% year-over-year to 47.2 MSEK, with EBITDA margin rising to 25% from 19% and EBIT margin to 16% from 11%.
H1 2025 revenue grew 11% year-over-year to 98.5 MSEK, with EBITDA margin at 23% and EBIT margin at 15%.
Strong order intake, including the largest order in company history (100-150 MSEK automation contract) and breakthrough deals in the semiconductor and automation sectors.
Strategic focus on direct sales in key markets, with new sales office in San Jose and plans for Tokyo and Germany.
Financial highlights
Q2 gross margin improved to 65% from 63% year-over-year.
Q2 EBITDA was 12 MSEK (up from 8 MSEK), EBIT was 7.7 MSEK (up from 5 MSEK).
H1 net income was 10.3 MSEK, up from 4.6 MSEK year-over-year.
EPS for H1 was 0.34 SEK (0.18 SEK in H1 2024).
Outlook and guidance
Management expects continued strong performance in H2, especially from US subsidiary TPA Motion and increased order flow at Piezo Motor and Sensapex.
2025 EBITDA forecast raised to 52-55 MSEK, a 70% increase over 2024.
New financial targets: 2026 EBITDA margin of 25-30% and EBITDA over 65 MSEK; 2027 EBITDA target above 85 MSEK.
Latest events from Acuvi
- Net sales up 16%–18%, Q4 up 25%; adjusted EBITDA positive, 2026 targets focus on growth.ACUVI
Q4 202526 Feb 2026 - Q3 2025 revenue up 32% year-over-year, with robust OEM/Industrial growth and margin gains.ACUVI
Q3 202526 Feb 2026 - Direct sales focus and cash flow positivity set the stage for ambitious growth targets.ACUVI
Business Update20 Nov 2025 - Stable Q3 margins, strong cash flow, and IFRS transition support positive 2024 outlook.ACUVI
Q3 202413 Jun 2025 - Sales declined but margins improved; new partnerships and capital support future growth.ACUVI
Q2 202413 Jun 2025 - Stark Q1-tillväxt och ökad direktförsäljning väntas driva fortsatt expansion.ACUVI
Q1 20256 Jun 2025 - Margins improved and 2025 EBITDA is set for strong growth on robust US demand.ACUVI
Q4 20245 Jun 2025